AI in Healthcare Grows From Pilot Projects to Core Infrastructure
Across global health systems, AI in healthcare is shifting from experimental tools to embedded infrastructure in diagnostics, genomics and drug discovery. Market outlooks point to this acceleration: the AI diagnostics market is forecast to climb from USD 4.2 billion (approx. RM19.3 billion) to USD 10.5 billion (approx. RM48.3 billion) by 2033, while AI in genomics is projected to grow from USD 4.8 billion (approx. RM22.1 billion) to USD 12.2 billion (approx. RM56.1 billion) over the same period. AI drug discovery is expected to expand from USD 3.7 billion (approx. RM17.0 billion) to USD 11.2 billion (approx. RM51.5 billion), supported by more than USD 2.5 billion (approx. RM11.5 billion) in pharma investment. These trends are driven by the promise of faster, more accurate care, from automated image analysis to personalised treatment plans. For Malaysian providers under pressure from rising chronic disease and specialist shortages, these maturing markets signal that medical AI adoption is moving into a pragmatic, deployment-focused phase rather than distant hype.
From AI Diagnostics to Genomics and Molecule Reconstruction
Concrete use cases are emerging along the entire clinical pipeline. In imaging, AI diagnostics tools now reach accuracy rates of about 97% for conditions such as diabetic retinopathy, and studies suggest they can cut diagnostic errors by half while improving outcomes by up to 30%. In genomics, more than 60% of research institutions already use AI tools, with 70% of healthcare providers reporting better patient outcomes driven by AI-based genomic insights, laying a foundation for personalised medicine. Upstream in discovery, AI platforms are analysing thousands of new drug candidates, while generative models can even reconstruct molecular geometries from Coulomb explosion imaging data, opening the door to tracking molecules through complex reactions. Regulatory support is catching up too, with authorities such as the FDA beginning to approve AI algorithms for drug design. Together, these advances form an emerging ecosystem where screening, risk prediction and targeted therapies are all augmented by algorithmic insight.
AI in Hospice Care: Quietly Reshaping the End-of-Life Experience
Beyond hospital walls, AI in hospice care and senior living is being designed as a behind-the-scenes companion rather than a replacement for clinicians. Hospice leaders describe AI’s most meaningful role as enabling personalisation of care at scale: spotting patterns in symptoms, comfort levels and psychological needs so teams can respond earlier and more precisely. AI can act as an early-warning system, monitoring subtle shifts in pain, sleep or caregiver stress across multiple data sources, prompting timely interventions before crises arise. Nurses and administrators also highlight its operational benefits, using AI to surface the right information at the right time, reduce duplicate documentation and compile complex histories in seconds. That efficiency translates directly into more bedside time and more attention to patient goals, preferences and family dynamics. Importantly, hospice providers stress strong guardrails and quality assurance so AI remains a clinical support tool, never a substitute for the human connection at the core of end-of-life care.
Guiding AI With Human and Community Insight
Real-world pilots show that the most successful medical AI adoption is guided by clinicians and communities, not just engineers. In the United States, the CoDiRA initiative is building AI-powered medical kiosks in pharmacies and community centres to address rural health gaps, but it grounds the technology in local relationships, culturally tailored design and clinical practice. Researchers acknowledge that factors like postcode and internet access still heavily shape health outcomes, so AI tools are co-designed with communities to improve trust and usability. Hospice innovators express similar themes: AI should propose, clinicians decide. They emphasise robust quality assurance programmes, clear clinical oversight and continuous monitoring of algorithm performance to catch bias or unsafe recommendations. These examples underline that AI in healthcare, whether in diagnostics or hospice workflows, works best as an assistive layer embedded in existing care models, with human judgment, ethics and community insight shaping when and how it is used.
Implications for Malaysian Healthcare: Opportunities and Gaps
For Malaysia, the rise of AI diagnostics, genomics and AI drug discovery offers a chance to ease specialist shortages, especially in rural and East Malaysian communities where access to cardiologists, oncologists or palliative care teams is limited. AI-assisted imaging could help front-line clinicians flag high-risk cases for referral, while predictive diagnostics and genomic tools could support more personalised treatment planning in tertiary centres. In hospice and long-term care, AI-driven documentation support, triage alerts and care-planning insights could relieve overstretched nurses and allow more time for counselling and family engagement. Yet several gaps remain: consistent broadband connectivity in rural areas, interoperable electronic medical records for training and deploying AI tools, and clear regulatory frameworks on data privacy, algorithmic transparency and liability. Addressing these foundations—alongside clinician training and public education—will determine whether Malaysia can translate global AI in healthcare breakthroughs into equitable, trusted improvements at the kampung and community clinic level.